Natalia Papargyri
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Natalia Papargyri has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Aurel Pui
Faculty of Chemistry, Alexandru Ioan Cuza University of Iasi, 700506 Iasi, Romania
1 shared publication Bo R. Hansen
Therapeutic Modalities, Roche Pharma Research and Early Development, Roche Innovation Center Copenhagen, 2970 Hørsholm, Denmark
1 shared publicationDennis J. Hansen
Therapeutic Modalities, Roche Pharma Research and Early Development, Roche Innovation Center Copenhagen, 2970 Hørsholm, Denmark
1 shared publicationElisabeth Christiansen
Department of Physics, Chemistry and Pharmacy, University of Southern Denmark, Odense M, Denmark
1 shared publicationErik D. Funder
Therapeutic Modalities, Roche Pharma Research and Early Development, Roche Innovation Center Copenhagen, 2970 Hørsholm, Denmark
1 shared publicationHelle Christiansen
Therapeutic Modalities, Roche Pharma Research and Early Development, Roche Innovation Center Copenhagen, 2970 Hørsholm, Denmark
1 shared publication
Latest Publications
- Open Access
- 1 March 2020
- Published by Elsevier in Molecular Therapy Nucleic Acids
- Vol. 19, 706-717
Chemical Diversity of Locked Nucleic Acid-Modified Antisense Oligonucleotides Allows Optimization of Pharmaceutical Properties
- 1 March 2020
- Published by Elsevier in Molecular Therapy Nucleic Acids
- Vol. 19, 706-717
Open AccessChemical Diversity of Locked Nucleic Acid-Modified Antisense Oligonucleotides Allows Optimization of Pharmaceutical Properties
- Open Access
- 1 January 2018
- Published by Elsevier in Drug Discovery Today
- Vol. 23 (1) , 101-114
Locked nucleic acid: modality, diversity, and drug discovery
- 1 January 2018
- Published by Elsevier in Drug Discovery Today
- Vol. 23 (1) , 101-114
Open AccessLocked nucleic acid: modality, diversity, and drug discovery
- 28 September 2016
- Published by Wiley in Chemical Biology & Drug Design
- Vol. 89 (3) , 289-296
Structure‐based discovery of novel US28 small molecule ligands with different modes of action
The human cytomegalovirus‐encoded G protein‐coupled receptor US28 is a constitutively active receptor, which can recognize various chemokines. Despite the recent determination of its 2.9 Å crystal structure, potent and US28‐specific tool compounds are still scarce. Here, we used structural information from a refined US28:VUF2274 complex for virtual screening of >12 million commercially available small molecule compounds. Using a combined receptor‐ and ligand‐based approach, we tested 98 of the top 0.1% ranked compounds, revealing novel chemotypes as compared to the ~1.45 million known ligands in the ChEMBL database. Two compounds were confirmed as agonist and inverse agonist, respectively, in both IP accumulation and Ca2+ mobilization assays. The screening setup presented in this work is computationally inexpensive and therefore particularly useful in an academic setting as it enables simultaneous testing in binding as well as in different functional assays and/or species without actual chemical synthesis.
- 28 September 2016
- Published by Wiley in Chemical Biology & Drug Design
- Vol. 89 (3) , 289-296
Structure‐based discovery of novel US28 small molecule ligands with different modes of action
The human cytomegalovirus‐encoded G protein‐coupled receptor US28 is a constitutively active receptor, which can recognize various chemokines. Despite the recent determination of its 2.9 Å crystal structure, potent and US28‐specific tool compounds are still scarce. Here, we used structural information from a refined US28:VUF2274 complex for virtual screening of >12 million commercially available small molecule compounds. Using a combined receptor‐ and ligand‐based approach, we tested 98 of the top 0.1% ranked compounds, revealing novel chemotypes as compared to the ~1.45 million known ligands in the ChEMBL database. Two compounds were confirmed as agonist and inverse agonist, respectively, in both IP accumulation and Ca2+ mobilization assays. The screening setup presented in this work is computationally inexpensive and therefore particularly useful in an academic setting as it enables simultaneous testing in binding as well as in different functional assays and/or species without actual chemical synthesis.